Targeting the MDK/c‐Myc complex to overcome temozolomide resistance in glioma
Abstract Background Temozolomide (TMZ), which is an alkylating agent, is the standard chemotherapeutic drug used for glioma treatment. However, the development of resistance to TMZ limits its efficacy. Thus, identifying novel therapeutic targets is necessary. Methods In this study, the levels of mid...
Saved in:
| Main Authors: | Xiaonan Xi, Xiaojing Ding, Qianqian Wang, Ning Liu, Bangmao Wang, Genbei Wang, Weilong Zhong, Yaxin Lu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ctm2.70359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Midkine (MDK) in cancer and drug resistance: from inflammation to therapy
by: Berna Yıldırım, et al.
Published: (2025-06-01) -
Coordinated changes in midkine expression and midkine-associated multiomic profile in glioma microenvironment
by: Mieszko Lachota, et al.
Published: (2025-08-01) -
Integrative single-cell and spatial transcriptomics analysis reveals MDK-NCL pathway’s role in shaping the immunosuppressive environment of lung adenocarcinoma
by: Yu Fu, et al.
Published: (2025-05-01) -
Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights
by: Hengzeng Li, et al.
Published: (2025-06-01) -
The Potential Role of C4 MYH11+ Fibroblasts and the MDK-SDC2 Ligand-Receptor Pair in Lung Adenocarcinoma: Implications for Prognosis and Therapeutic Strategies
by: Hongling Jia, et al.
Published: (2025-05-01)